PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
32.15%
Cash & equivalents growing 32.15% while TRAW's declined -16.79%. Peter Lynch would see this as a sign of superior liquidity management.
No Data
No Data available this quarter, please select a different quarter.
32.15%
Below half of TRAW's -16.79%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.78%
Below half of TRAW's -17.32%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-2.88%
Below half TRAW's -13.64%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.86%
Below half of TRAW's -12.77%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Below half of TRAW's -17.28%. Michael Burry sees a potential red flag for stagnation or capital shortage.
63.16%
Above 1.5x TRAW's 30.75%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.70%
Exceeding 1.5x TRAW's -8.12%. Michael Burry suspects ballooning short-term obligations vs. competitor.
49.30%
Above 1.5x TRAW's 12.79%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
49.30%
Above 1.5x TRAW's 0.18%. Michael Burry sees a potential leverage warning sign.
16.87%
Higher Common Stock (Book Value) Growth compared to TRAW's zero value, indicating worse performance.
-5.16%
≥ 1.5x TRAW's -1.64%. David Dodd sees higher yoy retained profits than competitor.
-13.18%
Less than half of TRAW's -82.35%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
26.52%
Below half TRAW's -53.22%. Michael Burry sees potential underperformance in building shareholder capital.
30.51%
Below half TRAW's -17.28%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-32.15%
Less than half of TRAW's 16.79%. David Dodd sees better deleveraging or stronger cash buildup than competitor.